Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
News Medical on MSN1d
GLP-1 agonists linked to fewer hospitalizations in alcohol use disorder patients
A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...
Medscape5d
Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes
GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome; CAD: Coronary artery disease; CHF: Congestive heart failure; CRF: Chronic renal ...
Medscape5d
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, versus Twice-daily Exenatide for Type 2 Diabetes
[11] The absence of severe hypoglycemia is consistent with the glucose-dependent insulinotropic mechanism of GLP-1 receptor agonists. The rates of confirmed hypoglycemia were similar between the ...
ahajournals.org4d
Abstract 4138604: Impact of GLP-1 Agonist on the Incidence of Atrial Fibrillation in Obese Patients Following Heart Failure Hospitalization
Glucagon-like peptide-1 (GLP-1) agonists have been shown to reduce cardiovascular risk in patients with obesity and diabetes, respectively. Meta-analysis of prospective trials looking at GLP-1 agonist ...
ahajournals.org4d
Abstract 4145444: GLP-1 Receptor Agonists And Clinical Events After Anthracycline-Based Chemotherapy: A Propensity Score-Matched Cohort Study
The role of GLP-1 receptor agonists for patients with cancer undergoing anthracycline-based chemotherapy remains unknown. Hypothesis: GLP-1 receptor agonists are associated with reduced mortality and ...
Daily4d
Risk of Pulmonary Aspiration During Anesthesia with GLP-1 Agonists, FDA Issues New Safety Warning
Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor agonists (GLP-1 RAs) about the risk of pulmonary aspiration during ...
pharmaphorum4d
Trial finds benefit for GLP-1 agonist in Parkinson’s
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...
GLP-1 RA use tied to lower rate of venous thromboembolism in diabetes
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
HealthDay on MSN14h
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
TCTMD2d
Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key
In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...
Medpage Today on MSN1d
GLP-1 Drugs Could Help People With Alcohol Use Disorder
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...